- Home
- UEC vs FOLD Comparison
UEC vs FOLD Comparison
Compare UEC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEC
- FOLD
- Stock Information
- Founded
- UEC 2003
- FOLD 2002
- Country
- UEC United States
- FOLD United States
- Employees
- UEC N/A
- FOLD N/A
- Industry
- UEC Other Metals and Minerals
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- UEC Basic Materials
- FOLD Health Care
- Exchange
- UEC Nasdaq
- FOLD Nasdaq
- Market Cap
- UEC 2.8B
- FOLD 2.9B
- IPO Year
- UEC N/A
- FOLD 2007
- Fundamental
- Price
- UEC $6.44
- FOLD $5.64
- Analyst Decision
- UEC Strong Buy
- FOLD Buy
- Analyst Count
- UEC 3
- FOLD 10
- Target Price
- UEC $10.08
- FOLD $16.22
- AVG Volume (30 Days)
- UEC 18.3M
- FOLD 4.5M
- Earning Date
- UEC 06-02-2025
- FOLD 08-07-2025
- Dividend Yield
- UEC N/A
- FOLD N/A
- EPS Growth
- UEC N/A
- FOLD N/A
- EPS
- UEC N/A
- FOLD N/A
- Revenue
- UEC $66,837,000.00
- FOLD $543,141,000.00
- Revenue This Year
- UEC $41,201.79
- FOLD $19.84
- Revenue Next Year
- UEC $25.78
- FOLD $23.18
- P/E Ratio
- UEC N/A
- FOLD N/A
- Revenue Growth
- UEC 70.62
- FOLD 28.25
- 52 Week Low
- UEC $3.85
- FOLD $5.62
- 52 Week High
- UEC $8.93
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- UEC 56.84
- FOLD 33.65
- Support Level
- UEC $6.46
- FOLD $6.00
- Resistance Level
- UEC $7.15
- FOLD $6.22
- Average True Range (ATR)
- UEC 0.40
- FOLD 0.19
- MACD
- UEC 0.01
- FOLD -0.01
- Stochastic Oscillator
- UEC 53.29
- FOLD 2.70
About UEC Uranium Energy Corp.
Uranium Energy Corp is engaged in uranium mining and related activities. The company is working towards fueling the demand for carbon-free nuclear energy, a key solution to climate change, and energy source for the low-carbon future. The company is advancing its next generation of low-cost, environmentally friendly, in-situ recovery (ISR) mining uranium projects. The company has two extraction-ready ISR hub and spoke platforms in South Texas and Wyoming. UEC also has seven U.S. ISR uranium projects with all of their permits in place, with additional diversified holdings of uranium assets across the U.S., Canada and Paraguay.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.